Literature DB >> 2456930

Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer.

T Stefenelli1, R Kuzmits, W Ulrich, D Glogar.   

Abstract

Twenty-one consecutive patients with testicular cancer treated with bleomycin, vinblastine, and cisplatin (PVB) were evaluated for acute vascular ischaemic events during chemotherapy. Angina pectoris occurred in 8/21 (38%) patients, a median 5.6 weeks after initiation of chemotherapy and persisted for 2-7 days. Raynaud's phenomenon was detected in seven (33%) subjects, transient ischaemia of the toes was found in six (29%) patients, one patient complained of migraine, but none had major cerebrovascular accidents. Patients with and without angina pectoris and/or Raynaud's phenomenon did not differ in respect of age, histology of tumor or medication. Ischaemia occurred at any time during the course of chemotherapy. No correlation was found between dosage of drugs and time of onset of ischaemic reactions. However, arterial occlusive event is a frequent and common toxicity and a result of treatment with PVB.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456930     DOI: 10.1093/oxfordjournals.eurheartj.a062542

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  15 in total

1.  Autonomic neuropathy after cisplatin based chemotherapy.

Authors:  P Richardson; B M Cantwell
Journal:  BMJ       Date:  1990-06-02

2.  Raynaud's of the tongue following chemoradiation for squamous cell carcinoma of the oropharynx.

Authors:  Amit Mittal; Bharat B Mittal
Journal:  Mol Clin Oncol       Date:  2016-12-07

Review 3.  Ischemic Heart Disease: Special Considerations in Cardio-Oncology.

Authors:  Dana Elena Giza; Fernando Boccalandro; Juan Lopez-Mattei; Gloria Iliescu; Kaveh Karimzad; Peter Kim; Cezar Iliescu
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-05

Review 4.  Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis.

Authors:  Saamir A Hassan; Nicolas Palaskas; Peter Kim; Cezar Iliescu; Juan Lopez-Mattei; Elie Mouhayar; Rohit Mougdil; Kara Thompson; Jose Banchs; Syed Wamique Yusuf
Journal:  Curr Atheroscler Rep       Date:  2018-02-08       Impact factor: 5.113

Review 5.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

Review 6.  Management of CAD in Patients with Active Cancer: the Interventional Cardiologists' Perspective.

Authors:  Dana Elena Giza; Kostas Marmagkiolis; Elie Mouhayar; Jean-Bernard Durand; Cezar Iliescu
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

Review 7.  Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Authors:  Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub
Journal:  Circulation       Date:  2019-03-26       Impact factor: 29.690

Review 8.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

9.  Chemotherapy for testicular cancer induces acute alterations in diastolic heart function.

Authors:  L D van Schinkel; P M Willemse; R W van der Meer; J Burggraaf; S G C van Elderen; J W A Smit; A de Roos; S Osanto; H J Lamb
Journal:  Br J Cancer       Date:  2013-08-06       Impact factor: 7.640

Review 10.  Vascular toxic effects of cancer therapies.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-26       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.